Welcome to our dedicated page for NewAmsterdam Pharma Company N.V SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company developing the oral CETP inhibitor obicetrapib for LDL-C lowering in patients at risk of cardiovascular disease. Through these regulatory documents, investors can review how NewAmsterdam reports its clinical progress, financial position and corporate actions.
Current reports on Form 8-K are used by NewAmsterdam to disclose material events such as quarterly financial results, corporate updates and the publication of investor presentations. For example, the company has filed an 8-K to furnish a press release announcing financial results for a recent quarter and to make an updated corporate investor presentation available as an exhibit. Such filings can give context on research and development spending, cash and marketable securities, and the status of key clinical and regulatory milestones.
NewAmsterdam also uses SEC filings to document equity-related matters, including inducement share option grants made under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). These disclosures outline the size of option grants, vesting schedules and exercise prices for new hires, providing insight into compensation practices and share-based incentives.
On Stock Titan, NewAmsterdam’s SEC filings are updated as they are made available from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections and clarify terminology. Users can quickly locate quarterly and annual reports when filed, review 8-Ks describing clinical and regulatory developments, and examine exhibits such as press releases and corporate presentations. This makes it easier to understand how NewAmsterdam communicates the evolution of its obicetrapib program, its collaboration and licensing arrangements, and other corporate information in its official regulatory record.
NewAmsterdam Pharma reported first quarter 2026 results and a broad clinical update. Revenue was $3.0 million, while net loss widened to $48.4 million from $39.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $707.3 million as of March 31, 2026.
The company highlighted ongoing Phase 3 programs for obicetrapib, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled, REMBRANDT with 323 patients enrolled, and RUBENS targeting about 300 patients. Interim PREVAIL analysis is planned for 4Q 2026 with results expected in 1Q 2027.
Regulatory decisions in Europe, the UK and Switzerland for obicetrapib and the obicetrapib/ezetimibe fixed‑dose combination are expected in 2H 2026, with potential launches by Menarini in 4Q 2026 in Germany and the UK. The company also described Alzheimer’s biomarker findings from the BROADWAY trial and plans a new trial in early Alzheimer’s disease in 2026.
NewAmsterdam Pharma Company N.V. reported first‑quarter 2026 results showing it remains a late‑stage, R&D‑focused biopharma with no approved products and ongoing losses. Revenue was modest at $3.0 million, coming mainly from product supply under the Menarini agreement.
Research and development spending was $38.0 million, down from the prior year as several Phase 3 LDL‑C trials completed, while selling, general and administrative expenses fell to $23.5 million. The company recorded a net loss of $48.4 million, or $0.40 per share.
Cash, cash equivalents and marketable securities totaled $707.3 million, supporting continued investment in the large PREVAIL cardiovascular outcomes trial and other studies of obicetrapib, including work on a fixed‑dose combination with ezetimibe and exploration in Alzheimer’s disease and diabetes‑related indications.
FMR LLC files an amendment to Schedule 13G reporting beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV common stock. The filing states FMR LLC holds 8,765,811 shares, representing 7.6% of the class, with sole dispositive power and no shared voting power reported. The amendment notes related power-of-attorney authority and references Exhibit 99 and an Exhibit 24 power of attorney.
NewAmsterdam Pharma Company N.V. is asking shareholders to vote at its June 2, 2026 annual general meeting in Amsterdam on nine proposals covering financial statements, governance and compensation.
Shareholders are asked to adopt the Dutch statutory annual accounts for 2025, discharge directors from liability for 2025, and instruct and ratify Deloitte Accountants B.V. as external auditor and independent registered public accounting firm for 2026. Two non-executive directors, John W. Smither and Janneke van der Kamp, are up for reappointment with proposed terms running until the 2030 annual meeting.
The agenda also seeks to extend the Board’s authority to issue ordinary shares and to limit or exclude pre-emption rights for up to five years, approve a 2026 Employee Stock Purchase Plan reserving 1,150,000 ordinary shares, and hold a non-binding advisory vote on 2025 compensation for named executive officers. Shareholders of record as of May 5, 2026 may vote in person, by proxy, telephone or internet, subject to the described deadlines and procedures.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Company N.V. is soliciting proxies for its 2026 Annual General Meeting to be held on June 2, 2026 at 5:00 p.m. CEST in Amsterdam. The agenda includes adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2025, discharge of directors, auditor instruction and ratification, director reappointments, extensions of authorizations to issue ordinary shares and to limit pre-emption rights, approval of a 2026 Employee Stock Purchase Plan (ESPP) reserving 1,150,000 ordinary shares, and a non-binding advisory vote on 2025 executive compensation.
The Record Date is May 5, 2026; Beneficial Owners must submit an Attendance Notice and supporting proof by 11:59 p.m. ET on May 31, 2026 (Cut-off Time). Audit fees paid to Deloitte were $1,071,000 for 2025 and $1,433,000 for 2024. Proxy voting options, quorum rules and vote thresholds for each proposal are described in the proxy materials.
NewAmsterdam Pharma Co N.V. director Louis G. Lange reported open-market sales of a total of 44,619 Ordinary Shares on March 11, 2026. He sold 44,173 shares at a weighted average price of $30.41 per share and 446 shares at a weighted average price of $31.23 per share. After these sales, he directly owns 10,360 Ordinary Shares. The prices reflect multiple trades in ranges from $30.11 to $31.31 per share.
NewAmsterdam Pharma Company N.V. resale filing shows planned and recent transfers of Ordinary Shares. The filing lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash. It also records that The LG Lange III Trust sold 28,186 Ordinary Shares on 03/06/2026 for $828,849.41.
This Form 144 excerpt documents resale activity by a trust and a warrant-related issuance; cash‑flow treatment for proceeds beyond the warrant exercise is not detailed in the excerpt.
NewAmsterdam Pharma director Louis G. Lange reported a mix of warrant exercises and share sales. On March 9, 2026, he exercised warrants to acquire 44,619 Ordinary Shares at $11.50 per share, leaving him with 54,979 Ordinary Shares held directly.
Separately, on March 6, 2026, a trust associated with him, the LGLange III Trust DTD10, sold 28,186 Ordinary Shares in open-market transactions at a weighted average price of $29.41 per share, within a range of $29.03 to $29.68, and reported no remaining indirect holdings.